Obuhangire bwa TG Therapeutics (TGTX) bwa Sikaati
AI forecast: TGTX
AI ebandika ekiruho ky'obusobozi bw'omubere gw'ekiseera ekiddako, ekigero ky'omubere gw'ebirungi, n'ekigero ky'omubere gw'omwezi. Okuhinduka kuhakirizwa hakurikira obusobozi bwa nyuma. Bino ni obuhangire bw'obusobozi, si obuhangire bw'okuhanga.
Ebiharwa by'omwaka guhera mu myezi 6 eyita
Premium erikahyora ebyifujiraho by'AI eby'omutengo mu nsi y'omunzi omu, wiiki emu n'omwaka omu ku kizigirwa kino n'ebirala byonna.
Unlock Premium🔒 Ekihugho ky'obuhangire bw'obusobozi
Ekihugho ky'obuhangire bw'obusobozi — buli kihuugho ky'omubere gya nyuma hafi n'obusobozi bwa nyakuri — ni ekigero cya Premium.
Unlock PremiumEbikwata ku Kitongole Kino
TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the acquisition, development, and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved diseases. The company is developing two treatments for hematologic malignancies, specifically relapsed and refractory non-Hodgkin lymphoma.
